as of 03-09-2026 10:52am EST
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
| Founded: | 1991 | Country: | United States |
| Employees: | N/A | City: | CONCORD |
| Market Cap: | 276.0M | IPO Year: | 1996 |
| Target Price: | N/A | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.08 | EPS Growth: | 27.27 |
| 52 Week Low/High: | $1.12 - $2.96 | Next Earning Date: | 05-22-2026 |
| Revenue: | $51,326,000 | Revenue Growth: | 30.68% |
| Revenue Growth (this year): | 20% | Revenue Growth (next year): | 9.60% |
| P/E Ratio: | -24.19 | Index: | N/A |
| Free Cash Flow: | 1.1M | FCF Growth: | -87.00% |
SEC 8-K filings with transcript text
Mar 2, 2026 ยท 100% conf.
1D
-2.95%
$2.46
Act: -15.81%
5D
-15.80%
$2.13
20D
-12.93%
$2.20
8-K
false000102021400010202142026-03-022026-03-02
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 02, 2026
(Exact name of Registrant as Specified in Its Charter)
Delaware
000-21937
68-0262011
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
1220 Concord Avenue, Suite 600
Concord, California
94520
(Address of Principal Executive Offices)
(Zip Code)
Registrantโs Telephone Number, Including Area Code: 925 288-6000
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: โWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) โSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) โPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) โPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (ยงโฏ230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (ยงโฏ240.12b-2 of this chapter). Emerging growth company โ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. โ
Item 2.02 Results of Operations and Financial Condition. On March 2, 2026, Cerus Corporation (the โCompanyโ) announced its financial results for its fourth quarter and fiscal year ended December 31, 2025. A copy of the Companyโs press release, entitled โCerus Corporation Announces Full-Year and Fourth Quarter 2025 Financial Results,โ is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto.
The information in this report, including the exhibit hereto, shall not be deemed to be โfiledโ for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits.
The following exhibit is furnished with this report:
99.1 Press release, dated March 2, 2026, entitled โCerus Corporation Announces Full-Year and Fourth Quarter 2025 Financial Results.โ
104 Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date:
March 2, 2026
By:
/s/ Kevin D. Green
Kevin D. Green, Chief Financial Officer
Jan 12, 2026 ยท 100% conf.
1D
-2.95%
$2.46
Act: -15.81%
5D
-15.80%
$2.13
20D
-12.93%
$2.20
8-K
false000102021400010202142026-01-112026-01-11
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 11, 2026
(Exact name of Registrant as Specified in Its Charter)
Delaware
000-21937
68-0262011
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
1220 Concord Avenue, Suite 600
Concord, California
94520
(Address of Principal Executive Offices)
(Zip Code)
Registrantโs Telephone Number, Including Area Code: 925 288-6000
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: โWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) โSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) โPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) โPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (ยงโฏ230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (ยงโฏ240.12b-2 of this chapter). Emerging growth company โ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. โ
Item 2.02 Results of Operations and Financial Condition. On January 11, 2026, Cerus Corporation (the โCompanyโ) announced its preliminary product revenue results for the fourth quarter and fiscal year ended December 31, 2025. A copy of the Companyโs press release, entitled โCerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2025 Product Revenue and Provides Outlook,โ is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto.
Such product revenue results as reported are preliminary, unaudited and subject to completion. The Companyโs independent registered public accounting firm has not audited or performed any procedures with respect to these preliminary results and does not express an opinion or any other form of assurance with respect thereto. The Companyโs financial closing procedures for the three months and year ended December 31, 2025 are not yet complete and, as a result, the final results upon completion of the closing procedures may vary from the preliminary estimates, and any such differences may be material. The Companyโs product revenue information presented herein should not be viewed as a substitute for the information set forth in the full financial statements prepared in accordance with U.S. generally accepted accounting principles, and undue reliance should not be placed on these preliminary product revenue results.
The information in this report, including the exhibit hereto, shall not be deemed to be โfiledโ for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits.
The following exhibit is furnished with this report:
99.1 Press release, dated January 11, 2026, entitled โCerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2025 Product Revenue and Provides Outlook.โ
104 Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date:
January 11, 2026
By:
/s/ Kevin D. Green
Kevin D. Green Chief Financial Officer
Nov 6, 2025
8-K
false000102021400010202142025-11-062025-11-06
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 06, 2025
(Exact name of Registrant as Specified in Its Charter)
Delaware
000-21937
68-0262011
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
1220 Concord Avenue, Suite 600
Concord, California
94520
(Address of Principal Executive Offices)
(Zip Code)
Registrantโs Telephone Number, Including Area Code: 925 288-6000
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: โWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) โSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) โPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) โPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (ยงโฏ230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (ยงโฏ240.12b-2 of this chapter). Emerging growth company โ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. โ
Item 2.02 Results of Operations and Financial Condition. On November 6, 2025, Cerus Corporation (the โCompanyโ) announced its financial results for its third quarter ended September 30, 2025. A copy of the Companyโs press release, entitled โCerus Corporation Announces Record Results for Third Quarter 2025 and Raises Full Year 2025 Product Revenue Guidance,โ is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto.
The information in this report, including the exhibit hereto, shall not be deemed to be โfiledโ for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits.
The following exhibit is furnished with this report:
99.1 Press release, dated November 6, 2025, entitled โCerus Corporation Announces Record Results for Third Quarter 2025 and Raises Full Year 2025 Product Revenue Guidance.โ
104 Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date:
November 6, 2025
By:
/s/ Kevin D. Green
Chief Financial Officer
CERS Breaking Stock News: Dive into CERS Ticker-Specific Updates for Smart Investing
AI Sentiment
Highly Positive
9/10
See how CERS stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "CERS Cerus Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.